

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

VOLUNTARY ANNOUNCEMENT

ASCENTAGE PHARMA TO PRESENT RESULTS FROM 2 CLINICAL STUDIES AT 2023 ESMO CONGRESS

Ascentage Pharma Group International (the “**Company**” or “**Ascentage Pharma**”) is pleased to announce today that it will present results from two clinical studies at the 2023 European Society of Medical Oncology (ESMO) Congress. These presentations include a Mini Oral featuring the latest data from a study of pelcitoclax (APG-1252), a Bcl-2/Bcl-xL dual-targeted inhibitor, combined with osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC); and a Poster on a study evaluating olverembatinib (HQP1351), the first and only China-approved third-generation BCR-ABL inhibitor, in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST).

As one of the most authoritative and influential congresses in oncology globally, the ESMO Congress showcases the latest results from some of the most cutting-edge research from around the world. This year, the ESMO Congress will take place from October 20, 2023 to October 24, 2023, local time, in Madrid, Spain.

These 2 clinical studies to be presented at the ESMO Congress this year are as follows:

Olverembatinib

Antitumor activity of olverembatinib (HQP1351) in patients (pts) with TKI-resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST)

- **Format:** Poster Presentation
- **Abstract number:** 5746
- **Category:** Sarcoma
- **First Author:** Haibo Qiu, MD, PhD, Sun Yat-sen University Cancer Center

APG-1252

Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC)

- **Format:** Mini Oral Presentation
- **Abstract number:** 5586
- **Category:** NSCLC (NSCLC, locally advanced)
- **First Author:** Yuxiang Ma, PhD, Sun Yat-sen University Cancer Center

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to obtain further approval for, or ultimately market, APG-1252 successfully.

By order of the Board
Ascentage Pharma Group International
Dr. Yang Dajun
Chairman and Executive Director

Suzhou, People's Republic of China, Aug 3, 2023

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon Dazhong as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng, Mr. Ren Wei and Dr. David Sidransky as independent non-executive Directors.